INTRODUCTION TO GUIDELINE FOR GOOD CLINICAL PRACTICE ICH E6(R2)
GUIDELINE FOR GOOD CLINICAL PRACTICE
INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2)
INTRODUCTION
Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety and well-being of trial subjects are protected, consistent with the principles that have their origin in the Declaration of Helsinki, and that the clinical trial data are credible. The objective of this ICH GCP Guideline is to provide a unified standard for the European Union (EU), Japan and the United States to facilitate the mutual acceptance of clinical data by the regulatory authorities in these jurisdictions. The guideline was developed with consideration of the current good clinical practices of the European Union, Japan, and the United States, as well as those of Australia, Canada, the Nordic countries and the World Health Organization (WHO). This guideline should be followed when generating clinical trial data that are intended to be submitted to regulatory authorities. The principles established in this guideline may also be applied to other clinical investigations that may have an impact on the safety and well-being of human subjects.
ADDENDUM
Since the development of the ICH GCP Guideline, the scale, complexity, and cost of clinical trials have increased. Evolutions in technology and risk management processes offer new opportunities to increase efficiency and focus on relevant activities. When the original ICH E6(R1) text was prepared, clinical trials were performed in a largely paper-based process. Advances in use of electronic data recording and reporting facilitate implementation of other approaches. For example, centralized monitoring can now offer a greater advantage, to a broader range of trials than is suggested in the original text. Therefore, this guideline has been amended to encourage implementation of improved and more efficient approaches to clinical trial design, conduct, oversight, recording and reporting while continuing to ensure human subject protection and reliability of trial results. Standards regarding electronic records and essential documents intended to increase clinical trial quality and efficiency have also been updated.
This guideline should be read in conjunction with other ICH guidelines relevant to the conduct of clinical trials (e.g., E2A (clinical safety data management), E3 (clinical study reporting), E7 (geriatric populations), E8 (general considerations for clinical trials), E9 (statistical principles), and E11 (pediatric populations)).
This ICH GCP Guideline Integrated Addendum provides a unified standard for the European Union, Japan, the United States, Canada, and Switzerland to facilitate the mutual acceptance of data from clinical trials by the regulatory authorities in these jurisdictions. In the event of any conflict between the E6(R1) text and the E6(R2) addendum text, the E6(R2) addendum text should take priority.
Author: European Medicines Agency, Source link
Clinical Research News
Upcoming Clinical Research Training and Conferences
-
on demandACROSS Global Training AcademyOnline
-
29 September 2023 – 02 October 2024SCDM (Society of Clinical Data Management)United States
-
21 – 23 May 2024InformaBelgium
-
03 – 04 June 2024The Society for Clinical Research Sites (SCRS)United States
-
16 – 17 July 2024The Society for Clinical Research Sites (SCRS)Australia
-
27 September – 29 October 2024The Society for Clinical Research Sites (SCRS)United States
다가오는 임상 시험
-
University of Novi Sad모병
-
The First Affiliated Hospital of Zhejiang Chinese...모병염증 반응 | 어린이의 뚜렛 증후군 | 음식 과민증중국
-
University of Rome G. MarconiUniversity of Bologna; University of the Italian Switzerland아직 모집하지 않음스트레스 | 불명증 | 산후 우울증이탈리아
-
Selcuk University아직 모집하지 않음게임화 | 간호학생 | Multiple Intelligence Theory | Disaster Nursing칠면조
-
NuvoAir Medical PCOptum, Inc.아직 모집하지 않음COPD | COPD 악화 | 심장/심장: 심부전
-
Regeneron PharmaceuticalsIntellia Therapeutics아직 모집하지 않음
-
Centro di Riferimento Oncologico - Aviano모병비소세포폐암 전이성 | ALK 유전자 돌연변이이탈리아
-
Institut de cancérologie Strasbourg EuropeContinuum Plus Santé; Plateforme nationale qualité de vie et cancer; WeShare아직 모집하지 않음
-
Musculoskeletal Injury Rehabilitation Research...The Geneva Foundation; Uniformed Services University (USU) of the Health Sciences; 1st Special... 그리고 다른 협력자들아직 모집하지 않음저수준 레이저 치료 | 광생물조절 요법 | 성능 향상 | 광의학 | 대퇴사두근 | 특수작전 준비태세
-
The Seventh Affiliated Hospital of Sun Yat-sen...Huizhou Municipal Central Hospital; Dongguan Hospital of Traditional Chinese Medicine; The...모병